Glycoconjugate vaccines are a safe, cheap and efficient way to improve human health. GlycoVaxyn AG has developed a proprietary technology that enables the manufacture of glycocconjugate vaccines in Escherichia coli. These bioconjugates  are composed of a antigenic polysaccharide coupled to a specific asparagine residue in an engineered protein carrier. The process is based on an enzymatic conjugation in living bacterial cells under very mild conditions. The conjugation of an antigenic polysaccharide to a carrier protein of choice occurs via an N-glycosidic linkage, resulting in a robust and reproducible process and yielding a highly defined product. The novel conjugation method has been used to develop various conjugate vaccines.The development of different glycoconjugate vaccines produced in bacterial cells will be sumarized.  Progress in the production and analysis of these bioconjugates is presented.

Glycoconjugate vaccines produced in bacterial cells through enzymatic conjugation

248th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.